"We congratulate Jeff on his appointment as independent Chairman of the Synthetic Biologics' Board. This important step strengthens Synthetic Biologics' corporate governance practices," stated Jeffrey Riley, Chief Executive Officer, President and Director of the Board at Synthetic Biologics. "Jeff's life science experience will be instrumental in guiding our business and strategic development initiatives."
Upon his appointment Mr. Kraws stated, "I look forward to working closely with Jeff as the Company continues to build its pipeline of synthetic DNA-based therapeutics and innovative medicines for serious illnesses. Transitioning the Chairman role to an independent board member should allow our CEO and his management team to focus on the operations of the Company, with the ultimate objective of increasing value for our shareholders."
About Synthetic Biologics, Inc.
Synthetic Biologics is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. Synthetic Biologics is developing, or has partnered the development of, product candidates for the treatment of pulmonary arterial hypertension (PAH), relapsing-remitting multiple sclerosis (MS), cognitive dysfunction in MS, fibromyalgia and amyotrophic lateral sclerosis (ALS). For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.
This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be iden
|SOURCE Synthetic Biologics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved